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Abstract: Understanding the skin penetration of nanoparticles (NPs) is
an important concern due to the increasing presence of NPs in consumer
products, including cosmetics. Technical challenges have slowed progress
in evaluating skin barrier and NP factors that contribute to skin penetration
risk. To limit sampling error and other problems associated with histologi-
cal processing, many researchers are implementing whole tissue confocal
or multiphoton microscopies. This work introduces a ﬂuorescence and
reﬂectance confocal microscopy system that utilizes near-IR excitation and
emission to detect near-IR lead sulﬁde quantum dots (QDs) through ex
vivo human epidermis. We provide a detailed prediction and experimental
analysis of QD detection sensitivity and demonstrate detection of QD skin
penetration in a barrier disrupted model. The unique properties of near-IR
lead-based QDs will enable future studies that examine the impact of
further barrier-disrupting agents on skin penetration of QDs and elucidate
mechanistic insight into QD tissue interactions at the cellular level.
© 2011 Optical Society of America
OCIS codes: (160.4236) Nanomaterials; (170.1790) Confocal microscopy; (170.3880) Medi-
cal and biological imaging.
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1. Introduction
Theincreasingpresenceofnanoparticles(NPs)inconsumerproductsandtechnicalapplications
has indicated a need to understand their interaction with the human system. To this end, a
number of studies have investigated the ability of NPs to penetrate the skin. Most recent studies
suggest that intact skin is an adequate barrier for hydrophilic NPs of polymeric [1–3], metal
oxide [4,5], and semiconductor quantum dots (QDs) [6–8]. However, when barrier is impaired
there appears to be an increased ability for NPs to penetrate the skin and interact with the local
cell types and the body system [6–11]. Since most NPs studied thus far are larger than the size
threshold for renal ﬁltration [12], studies have suggested their ability to remain in the body [13]
and potentially to cause long terms problems in a variety of cell types and NP types [14–16].
The ﬁeld of NP skin penetration is largely built on research into the percutaneous absorption
of other substances. Evaluation of percutaneous absorption has been a subject of investigation
for a number of years, and the ﬁeld of transdermal drug delivery has encouraged the develop-
mentofefﬁcient detection systemsformolecular targets,including analysisofacceptor solution
in a static or ﬂow-through diffusion cell, in vivo systemic distribution, histological analysis, and
whole-tissue imaging in the skin [17–19]. Similarly, as interest in the diffusion of NPs through
the skin has grown, so too has the technology that endeavors to understand these phenomenon.
However, when attempting to evaluate toxicological effects of skin penetration, low frequency
events may be important and so factors such as detection limits and the state of the nanoparticle
(i.e. dissolved ions or intact NPs) in the skin become increasingly critical.
One of the most promising ways to address these problems is through development of novel
imaging modalities. For imaging of NPs, the possible modalities depend on the physical char-
acteristics of the NP. The most commonly implemented form of advanced microscopy is that of
ﬂuorescent confocal microscopy. Fluorescent confocal imaging provides advantages in the ex-
clusion of defocused light using a pinhole, and therefore allows optical sectioning of samples.
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in practice, but some examples of whole tissue microscopy have been reported. Richard Guy’s
group has been one of the pioneers in this area, using confocal microscopy to evaluate the skin
penetration of a variety of ﬂuorescent polymeric NPs [1–3,20]. For example, a 2004 study by
Alvarez-Roman et al. found that FITC labeled polystyrene NPs of 20 nm and 200 nm diameter
were unable to penetrate porcine stratum corneum [1,2]. For QDs, a class of hard semiconduc-
tor NPs, our research was unable to ﬁnd appreciable skin penetration using green ﬂuorescent
QDs and whole tissue confocal microscopy [6]. Robert Langer’s group has also used this tech-
nique to support reported increased skin penetration of QDs with sonophoresis and sodium
lauryl sulfate treatment [21]. However, in all of these studies visible range whole tissue con-
focal microscopy is a minor supporting technique, since epidermal scattering and absorption
limit the penetration depth of light, both in the acceptable laser excitation powers as well as the
returned ﬂuorescence. Multiphoton microscopy overcomes the excitation and average power
limitations of visible range confocal microscopy by using femtosecond pulses of near-IR light
at twice the excitation wavelength, thereby achieving greater imaging depth in the skin. The
technique functions by 2-photon ﬂuorescent excitation or second harmonic generation (SHG)
of the target analyte, and has detected ZnO NPs using SHG [4,22,23]. One study has even been
able to put the technique into practice and demonstrate an increased skin penetration of ZnO
NPs with barrier disruption by chemical penetration enhancers [24]. These studies are signiﬁ-
cant, as ZnO is an important particle that is commonly used in topically applied sunscreens, but
its commonly used dominant emission peak at 385 nm limits the detection depth achievable.
To attempt to address these limitations, other techniques such as optical coherence tomography
and coherent anti-stokes raman spectroscopy have been implemented, but little literature exists
on their application in the skin [5,25,26].
Our work examines the potential of both a near-IR excitation source and a near-IR emit-
ting QDs to evaluate whole tissue skin penetration of NPs. QDs are a category of NPs that
have shown potential as a model for other hard insoluble metallic and metal oxide NPs, and
are of primary interest in the electronics and biomedical research ﬁelds. They provide advan-
tages in biomedical imaging due to their broad excitation band, high photobleaching threshold,
ease of functionalization, and stability. However, no studies currently exist in the literature that
utilize whole tissue microscopy to localize the penetration proﬁles of near-IR QDs through
the skin. Additionally, despite work determining the whole-body distribution of functionalized
near-IR QDs and targeting towards tumor tissues [27–29], we are unable to locate any stud-
ies that examine near-IR QD skin penetration proﬁles and the impact of skin barrier status on
skin penetration using any techniques. Our system, reported herein, endeavors to overcome the
limitations of visible range whole tissue microscopies by establishing a completely near-IR
confocal microscopy system. We have developed an optimized near-IR excitation and emission
confocal system that we have fully characterized and validated to allow the imaging of QDs
through the epidermis and demonstrated its sensitivity through an ex vivo human skin sample.
Our system shows potential to allow the evaluation of skin penetration proﬁles for near-IR QDs
and increase understanding of NP penetration mechanisms and translocation through skin and
other tissues.
2. Materials and methods
2.1. Instrumentation
For these experiments, a Lucid VivaScopeTM reﬂectance confocal microscope prototype (Lu-
cid, Inc., Rochester, NY) was rebuilt to allow imaging using both 660 nm and 785 nm laser
wavelengths. Our schematic highlights the important components of the system (Fig. 1). The
inclusion of a 664 nm long pass ﬁlter (LP02-664RS, Semrock Corp., Rochester, NY) allows the
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with a visible to near-IR coating (VIS-NIR coating, Edmund Optics, Barrington, NJ), fold
mirrors with a protected silver coating (ER.2, Newport Corp., Irvine, CA), an enhanced alu-
minum polygon (07 coating, Lincoln Laser Corp., Phoenix, AZ), a dichroic mirror to com-
bine beam paths (LaserMUX 659, Semrock Corp., Rochester, NY), and a long wavelength sili-
con avalanche photo-diode (APD) detector (C5460/S8890 custom module, Hamamatsu Corp.,
Bridgewater, NJ) were selected as determined by the manufacturer’s speciﬁcations. Scanning,
timing, and collection systems used were based on designs reported previously [30]. The 660
nm and 785 nm illuminating laser beams were scanned across the sample by the polygon and
galvanometric mirrors and relayed into the 30x 0.9-NA water immersion objective (Photon
Gear, Rochester, New York), with 5x magniﬁcation. The reﬂected and ﬂuorescently excited
light was then relayed back out through the pinhole (138 μm diameter) and to the APD. The
effective ﬁeld of view for our 10 bit 976x980 pixel image is 0.319 mm x 0.323 mm, yielding a
pixel pitch of 0.327 μm x 0.329 μm per pixel. Axial scanning is performed using a micrometer
to move the stage in the z-direction. To determine system resolution, a technique developed in
previous studies to achieve Nyquist sampling and a smooth modulation transfer function on a
single edge target was used [31]. Using this technique, we found lateral and axial resolutions
of 0.6±0.02 μm and 4.8±0.15 μm for the 660 nm laser and 0.8±0.03 μm and 2.4±0.08 μm
for the 785 nm laser. Lower axial resolution observed with the 660 nm laser is due to the apoc-
hromatic coatings in the objective, the larger effective pinhole size for the 660 nm laser, and
relative beam quality of the laser source.
2.2. Estimation of sensitivity
The performance of a ﬂuorescence imaging system in the skin depends on a number of factors.
Here we will account for the known optical parameters in order to reach a prediction of sensitiv-
ity. Benchmarking sensitivity measurements by theoretical approximation of expected signal is
an important task when approaching an imaging problem where an unknown concentration of a
substance in a biological milieu is the analyte. To achieve this for our system, the performance
of each system component is measured or estimated from manufacturer speciﬁcation and the
reﬂectivity or transmitivity multiplied together at the 660 nm and 785 nm wavelengths. As such,
the expression that includes the lens entry and exit transmitivity (TLλi), the mirror reﬂectivities
(RMλi), the dichroic mirror reﬂectivity (RDλi), the galvo reﬂectivity (RGλi), the polygon reﬂec-
tivity (RPλi), the polarizing beamsplitter surface transmitivity (TPB), the polarizing beamsplitter
internal surface reﬂectivity (RPB), the objective pupil area (AP), the magniﬁed beam area at the
pupil (AB), and the objective transmitivity (TOb) provides an estimate of the transmitivity be-
tween the laser source and the focal plane (Eq. (1)). To condense the descriptive equation, each
component factor is raised to the power of its number of occurrences (lenses have an entry and
an exit value) in the beam path as depicted (Fig. 1).
TSFPλi =( TLλi)8(RMλi)4(RDλi)(RGλi)(RPλi)(TPB)2(RPB)

AP
AB

(TOb) (1)
To test the accuracy of our estimates, we compared the predicted system throughput with the
actual laser power throughput for 660 nm in the system path up to the focal plane. By testing at
several powers, we found an average power throughput at 660 nm of 18% before the objective,
as compared with a prediction of 19%. The minor disparity between our predicted and exper-
imental values may be due to some polarization rejection of the laser source. The theoretical
objective transmitivity is unreported by the manufacturer across our range of wavelengths, but
we found experimentally that the beam at 660 nm passed 17% of the laser power present. These
values are used in subsequent power approximations.
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Fig. 1. The basic optical design for the system used in these experiments. Reﬂectance (785
nm) and ﬂuorescence (660 nm excitation) sources are pumped into a laser scanning confo-
cal microscopy system.
To estimate the ability of our system to measure light that returns to the detector from a ﬂu-
orescent probe, the noise equivalent power (NEP) of the detector is used. NEP is a commonly
quoted efﬁciency metric that describes the needed amount of power to equal the inherent de-
tector noise. For our detector, the manufacturer speciﬁed NEP is 0.15 pW/
√
Hzat the optimal
sensitivity wavelength of 940 nm normalized to a 1 Hz bandwidth modulation. The NEP is
inversely proportional to the photo sensitivity, whose wavelength dependent characteristics are
reported by the manufacturer. Thus, a wavelength distributed NEP response with relative values
across the active range of our system (NEP Detectorλi) can be estimated. This value must then be
transformed for the bandwidth used in our system, which requires division by the square root
of the dwell time in seconds (tdwell). The noise equivalent power level generated at the focal
plane at a given wavelength (NEP FPDλi) then scales by the component efﬁciency between the
focal plane and the detector, as depicted in the system schematic (Fig. 1), which increases the
amount of power that QDs in the focal plane must generate to achieve NEP.
NEP FPDλi =( NEP Detectorλi)

√
tdwell

(TOb)(TLλi)10(RMλi)3(RGλi)(RPλi)(TPB)2(
1
2
RPB)
−1
(2)
The objective solid angle (Ω) is another important factor in the microscope that decreases
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dipole pattern [32], and we assume random orientation of the QDs in the focal plane, which re-
sults in a uniform spherical average emission (ΩSphere =4π). However, the collection is limited
by the numerical aperture of the objective (NA) and the refractive index of the medium (RI),
and scales the collected QD ﬂuorescence by the proportion of the objective solid angle to the
whole angle of the emission sphere.
Ω = 2π

1−cos

arcsin

NA
RI

(3)
Since the system and detector performance is strongly dependent on wavelength, a realistic
representation of the QD emission peak is used. For this purpose, the manufacturer reported
spectroscopic proﬁle of our QDs results in a semi-Gaussian distribution with a FWHM of 200
nm (Fig. 2(A)). This normalized proﬁle is represented by the term IQDλi. For a speciﬁed peak
wavelength, the expression is numerically integrated (25 nm step size) from 200 nm to 1600
nm using the corresponding values for components to yield the NEP needed at the focal plane.
NEP QD =
4π
Ω
λi=1600 
λi=200

IQDλi

NEP FPDλi

dλi (4)
Additionally, since we wish to ultimately allow the imaging of QDs through epidermal tissue,
the expression can be expanded to include the non-reduced tissue scattering coefﬁcients (μsλi),
calculated from literature values for the reduced scattering coefﬁcient (μ 
sλi) and the anisotropy
factor (g) in similarly sourced human skin [33–38], and absorption coefﬁcients (μaλi) from the
literature for ex vivo human tissue [39]. The non-reduced scattering coefﬁcients were selected
based on wavefront error Strehl ratio comparison to scattering coefﬁcients, which found that
the reduced scattering coefﬁcients are too low to predict the proper Strehl effect, and suggested
that non-reduced scattering coefﬁcients are on the right order. A ﬁxed depth (z) of 100 μm
(Eq. (5)) was selected to represent the average thickness of human epidermis and provides an
estimate of imaging ability through human epidermis.
NEP QD−epi =
4π
Ω
λi=1600 
λi=200

IQDλi

NEP FPDλi


e
z
	
μsλi+μaλi


dλi (5)
The next phase of the model is the determination of optimal laser wavelength and the laser
power needed to achieve NEP by exciting the QDs with that wavelength. We ﬁrst selected a
QD sample with a known concentration and a peak at the optimal wavelength determined using
our calculations, and measured the absorbance (Fig. 2(A)). The Beer-Lambert law can then be
used to determine the extinction coefﬁcient (ελ) at each wavelength, and this value substituted
into the equation established for use in CdSe/ZnS QDs [40] and validated in PbS QDs [41] for
a single QD absorption cross section (Cabs, cm−2)
Cabs =
2303ελ
NA
(6)
where NA is Avogadro’s number. To determine the laser power needed to achieve NEP at the
detector, the estimated QD power generation (Fig. 3) determined in Eq. (5) is transformed into
units of Wc m −2 using the absorption cross section (Cabs). For this portion of our estimate, the
QDs are assumed to reside in the beam waist with a uniform illumination. With the inclusion of
the manufacturer’s speciﬁed QD quantum yield (QY) and proportion of ﬂuorescence collected
in the dwell time, the laser ﬂuence needed at the focal plane can be calculated. The Evident
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light is reduced by the proportion of QD ﬂuorescence that is released during the dwell time,
which is determined by the ﬂuorescence lifetime reported in the literature for the PbS QDs used
in our experiments [42]. Since the normal excitation lag time is on the order of picoseconds, it
is unnecessary to include this in the calculation. Fluorescence emission is commonly modeled
for QDs to follow an exponential decay of the formula e−t/τ where τ is the ﬂuorescence decay,
but for the Evident Technologies PbS QDs a two component ﬁt of the form A1exp(−t/τ1)+
A2exp(−t/τ2) has been found to be more descriptive [42]. For our samples, the established
two component values from Hyun et al. will be implemented, and so the proportion of signal
collected becomes the integral of the decay curve at the pixel dwell time divided by the integral
of the decay curve as t → ∞, which we will refer to as IDT (0.24 in this case). The radius of the
Airy Disk for the laser is used to estimate the effective focused laser spot area, a function of
the objective numerical aperture (NA) and the laser wavelength (λL), to correct for laser power
density, yielding a laser power input distribution in units ofWc m −2. Since the absorption cross
section of a QD is much smaller than the diffraction limited beam waist focal spot, the area
ratio is an important factor in determining the relative amount of laser power in Watts needed
at the focal plane (NEP LFP) to achieve detector NEP.
NEP LFP =( NEP QD)

π

0.61λL
NA
2
[(QY)(IDT)(Cabs)]
−1 (7)
To determine the power needed to achieve NEP at the laser source, the NEP LFP (Eq. (7)) is
then divided by the power loss from the focal plane to the source as described above (Eq. (1)).
NEP Laser =( NEP LFP)

TSFPλi
−1 (8)
To determine the impact of imaging through the skin, the NEP QD−epi term expressed in
Eq. (5) is then substituted into Eq. (7) to yield the noise equivalent power that . This value is a
best-case scenario, since the Strehl ratio of the beam decreases with increasing imaging depth
in tissue.
NEP LFP−epi =( NEP QD−epi)

π

0.61λL
NA
2
[(QY)(IDT)(Cabs)]
−1 (9)
The expression can be ﬁnalized in the same form as Eq. (8) with the additional inclusion of
skin scattering (μsλi) and absorption (μaλi) as discussed above through 100 μm of epidermis (z)
to yield an increase in the needed laser power.
NEP Laser−epi =( NEP LFP−epi)

TSFPλi
−1	
e
z(μsλi+μaλi)


(10)
2.3. Quantum dot imaging
Near-IR QDs with a lead-sulﬁde core and an emission peak of 900 nm in toluene were pur-
chased from Evident Technologies Inc. (Albany, New York) for our imaging studies. The ab-
sorbance proﬁle and quantum yields were measured to ensure precise prediction of the system
response to the QDs (Fig. 2(A)). To allow the imaging of QDs in a vertical conﬁguration in
solution, PDMS microwells (100 μm diameter by 10 μm deep) were ﬁlled with QDs at a series
of concentrations and clamped between a glass coverslip and a microscope slide (Figs. 2(B)
and 2(C)). This procedure excluded the QD solution from the surrounding areas and allowed
background signal to be collected in the same frame as the QD signal and separated using signal
processing in Matlab (Fig. 2(D)). Before each imaging session, the laser power was calibrated
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Fig. 2. Pictorial representation of an example normalized emission and absorbance curves
(A) for the QDs used in these experiments. To enable imaging in the upright position,
the PDMS microwells (B) of 100 μm diameter and 10 μm depth are ﬁlled with QDs and
clamped as shown (C). Clamping the QD ﬁlled PDMS microwells (ii) between coverglass
(iii) and a microscope slide (i) allows the imaging of a ﬁlled well. The QD signal (λmax=900
nm) can quite clearly be separated from the PDMS well.
to ensure accurate measurements. For imaging through a separated epidermis, the same setup
is used with the addition of an ex vivo human epidermis between the PDMS microwells and
the coverslip that we separated as described below.
2.4. Skin preparation
Our ex vivo human skin epidermis samples were obtained fresh from de-identiﬁed healthy adult
donors following abdominoplasty or mammoplasty (Strong and Highland Hospitals, University
of Rochester, NY), and stored at 4◦C. Usage was approved by the University of Rochester Re-
search Subjects Review Board. Within 6 hours of the surgical procedure, skin samples were
rinsed with sterile 1x phosphate buffered saline (PBS), treated with 0.4 mL fungizone (Invitro-
gen) in 500 mL sterile 1x PBS for 10 min, and rinsed again thoroughly with 1x PBS. To allow
the diffusion of our epidermal separating agent, subcutaneous fat was removed and the dermis
thinned. The skin samples were then transferred to fresh 100 mm sterile tissue culture plates
with gauze and incubated overnight at room temperature in 12 mL of 0.25% Dispase (Gibco
Inc.) in a sterile cell culture hood with the stratum corneum exposed to the air. The epider-
mis was then separated from the dermis using tweezers and used for imaging immediately. To
demonstrate instrument proof of principle in skin, 30 μLo f1 0μM PbS QDs in toluene were
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Fig. 3. Estimation of the power needed to be generated by QDs in the focal plane (A).
The noise equivalent power (NEP) for the detector is scaled by the peak width of the QDs,
the collection angle, and the system components. A clear minimum is observable in the
∼900 nm wavelength emission peak range. Using the measured absorbance to estimate the
absorption cross section then allows the minimum laser power needed to achieve NEP on a
single QD (note: in practice this is limited by blinking) at a range of laser wavelengths, and
it is observed that there is a power minimum at the 600-700 nm wavelength range (B), for
which a 660 nm laser line was chosen. When the power limitations of our excitation source
is included, the system response to a range of QD concentrations is able to be estimated
(C).
applied to full thickness ex vivo human skin tape stripped (20x, Scotch 3M 3750 clear packing
tape, USA) as described previously, [43] incubated for 24 hours with skin viability maintained
by sitting on a KGM-SF (Gibco Inc.) soaked gauze pad with the stratum corneum exposed to
the air, and used for imaging immediately thereafter.
3. Results and discussion
3.1. Sensitivity estimates
The predictions of system performance described above are useful in the estimation of antici-
pated sensitivity and determination of realistic limits for a given technique. With implementa-
tion for our detector and model QD emission distribution, the minimum NEPs calculated using
Eq. (4) for QDs alone and Eq. (5) for QDs through 100 μm epidermis yield NEP minimums
at 875 nm peak QD emission (Fig. 3(A)). This optimal value is close to that of the detector
sensitivity, but the steep falloff of the detector (1100 nm cutoff) and the 200 nm FWHM of
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range of our system, necessary power to achieve detector NEP ranges over 5 orders of magni-
tude (Fig. 3(A) inset). When an absorbance curve for QDs of this peak emission is converted to
absorption cross section and included with the losses from objective solid angle, focal spot size,
and system components, the resultant power needed to achieve NEP for a single QD can be esti-
mated using Eq. (8) for QDs alone and Eq. (10) for QDs through 100 μm epidermis (Fig. 3(B)).
We plot the value from 200 nm to 1600 nm, and ﬁnd a clear minimum power needed to achieve
detector NEP in the range of 600-700 nm (Fig. 3(B)). Thus, a laser line of 660 nm wavelength
is selected. Our estimates suggest that the necessary laser power to observe a single QD is 5
Watts, with 7.3 Watts needed to detect a single QD below the thickness of a human epidermis.
Such a high laser power is problematic due to cost, safety concerns, and destruction of the tissue
sample. However, single ﬂuorophore imaging is not vital to the goals of whole tissue skin pen-
etration imaging and is not commonly achieved in other techniques. To provide an estimation
of the minimum number of QDs in the focal plane needed to achieve NEP with varying laser
power, Eq. (10) is divided by the number of QDs in the image plane for a given laser wave-
length and plotted (Fig. 3(C)). The graph demonstrates that our laser currently in use (135 mW
at 660 nm) provides greater than NEP signal with 38 QDs in the focal plane, and 57 QDs in
the focal plane through 100 μm epidermis. If these values are normalized to the experimentally
determined lateral resolution (0.59 μm at 660 nm) the diffraction limited spot size, sensitivities
of approximately 5.7 fmol/cm2 of QDs on the slide and 8.7 fmol/cm2 QDs through 100 μm
epidermis are achievable. The total applied dose in our previous QD skin penetration studies
has been on the order of ∼ 3 pmol/cm2, which suggests that our microscope will be able to de-
tect as little as 0.2% of the applied dose on glass and 0.3% of the applied dose through 100 μm
epidermis [6,10]. If our laser power is increased to 1.5 W at the source (around 40 mW at the
sample surface), a value that is achievable using a krypton ion laser, the number of QDs in the
beam waist needed to reach NEP drops to 4 on glass and 6 through 100 μm epidermis, which
corresponds to 0.61 fmol/cm2 on glass or 0.92 fmol/cm2 through 100 μm epidermis. These
values correspond to 0.02% and 0.03% of the applied dose, respectively. Direct comparison to
existing techniques is challenging, as few studies deﬁne their system sensitivities in the same
fashion. However, our predicted sensitivity establishes the viability of whole tissue confocal
microscopy in the near-IR as a technique with the potential to provide valuable information
about permeation of substances through the epidermis with sub-cellular level lateral and axial
resolution
3.2. Experimental validation and model comparison
To determine whether the system in practice holds up to its theoretical predictions, measure-
ments of ﬂuorescence intensity from QDs at various concentrations have been executed. As
described in the materials and methods section, we suspended various concentrations of QDs
in PDMS microwells clamped tightly between the coverslip and a microscope slide. The pres-
ence of 100 μm diameter microwells enables the background to be calculated from the same
image as the QD signal, allowing for a facile representation of signal to noise within a sam-
ple. Each experiment was averaged over 6 different microwells at each concentration, and the
curve repeated at 3 laser power levels (1.6 mW, 2.4 mW, and 3.9 mW at the focal plane, data
not shown). In the high laser power case (3.9 mW at the focal plane), the signal gained from
the QDs is distinguishable from background down to a concentration as low as 0.1 μM, and
increases linearly over two orders of magnitude to a concentration of 10.0 μM (Fig. 4). When
the QDs are imaged through separated human epidermis, there is a substantial decrease in the
signal intensity across a range of concentrations, with the lowest detectable concentration of
QDs at 2.0 μM. The imaging of a known concentration of a ﬂuorescent probe to determine its
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Fig. 4. Signal response of system to QDs across a range of concentrations in the microwell
and through ∼100 μm separated human epidermis with a laser power of 3.9 mW at the
focal plane. Background noise is also plotted, and is calculated from the same frames as
the signal.
limit of detection is an important task when attempting to determine the ability of the a system
to detect an unknown concentration of the probe in a tissue sample. Our technique of placing
a known concentration of QDs behind approximately 100 μm of human epidermis allows for
an accurate determination of the lower limit of detection in our system in practice, with the
exception of scattering that would occur from apical QDs residing in the upper layers of the
epidermis.
In order to compare our results to varied concentrations of QDs to our predictions, it is
necessary to determine the predicted response to the number of QDs in a volume rather than
the previously described area calculation. To do so, the number of QDs detected are scaled
to the focal volume as determined by the lateral resolution (0.59 μm) and axial resolution
(4.75 μm) of our system at 660 nm in practice. When plotted over the range of concentrations
tested, the predictive measure matches well to experimental data (Fig. 5). For QDs imaged
in the microwell alone and through human epidermis, our experimental ﬂuorescent intensities
matched expected values at low concentrations, but did not attain predicted intensity at higher
concentrations. This may be caused by the assumption of uniform excitation efﬁciency of QDs
in the focal plane, and the higher deviation from the model present when imaging through
human epidermis may suggest a limit of epidermal scattering estimation or greater thickness of
ex vivo separated epidermal tissue than expected. Differences are relatively minor at all tested
QD concentrations. These values suggest that our system is operating at a near-ideal efﬁciency,
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Fig. 5. The behavior of the experimental data follows the model. The improved theoretical
sensitivity is expected, as we use idealized versions of the laser beams, QDs, and other
components as well as scattering and absorption coefﬁcients from the literature.
and inform a prediction of the ultimate limit of our sensitivity in practice.
3.3. QD skin penetration
Demonstration and calibration of the imaging system using QDs in microwells through sepa-
ratedepidermisnominallyveriﬁedthepredictedsystemperformance.Thenextstepisexecution
of skin penetration evaluation using topically applied QDs. To this end, QDs at stock concentra-
tion were applied to the skin in their toluene vehicle. Toluene is known to penetrate mammalian
skin in high levels [44,45], and a 24 hour application procedure of QDs in organic solvent with
additional barrier disruption through mechanical tape-stripping disruption provides an experi-
mental model for potential incidental exposure to QDs in the workplace through damaged skin.
Results ﬁnd that skin images from the reﬂectance channel are strongly degraded even close to
the surface of the skin (Fig. 6(A)), but cellular borders can still be observed (red arrows). QD
ﬂuorescence evaluation yields a strong signal (Fig. 6(B)) that can be traced into the tissue depth
(Fig. 6(C)). A much slower drop-off in signal is clear versus the reﬂectance in depth, and when
the ratio of these numbers is determined, the effective ﬂux rate is plotted. Additional noise is
present when imaging deeper in the tissue, but the curve suggests partitioning of the toluene-
containing QDs at the stratum corneum/ epidermal transition and a steady diffusive release into
the epidermis. When the QD ﬂuorescence and skin reﬂectance proﬁles are averaged over 6 loca-
tions in the skin (Fig. 6(D)), a consistent presence of QDs into the epidermis is clear, conﬁrming
the ability of our system to evaluate the skin penetration of QDs under relevant experimental
conditions.
Since ﬂuorescence is one of the key mechanisms that has been used to evaluate the skin pen-
etration of NPs, understanding the technical limitations of evaluation techniques has important
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Fig. 6. Skin penetration of 900 nm peak emission PbS QDs in toluene. The reﬂectance sig-
nal close to the surface of the skin is degraded by the highly scattering QDs and toluene
barrier disruption (A). However, some cell borders can still be resolved (arrows). The QDs
provide a strong ﬂuorescence signal at the same plane (B). When these proﬁles are plot-
ted, a clear permeation of QDs into the epidermis is observable relative to the collected
reﬂectance signal (C). The ratio of these values at each dose provides a steady-state ﬂux
curve determination, whose shape suggests that there is some partitioning of the toluene
solvated QDs at the stratum corneum/epidermal junction with a steady release through the
epidermis thereafter (C). The average of 6 measurement locations yields a curve exhibiting
the average permeation of PbS QDs into the epidermis (D).
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cology. Noticeably lacking from all but the most rigorous of publications is an estimation of the
minimum number of NPs that must be present to be detectable, and none that we have been able
to ﬁnd utilize ﬂuorescence microscopy except as a supporting technique. In fact, only one study
that we are currently aware of has been able to use whole tissue microscopy to determine a skin
penetration proﬁle of NPs. Kuo et al. have used second harmonic generation with multiphoton
microscopy to ﬁnd a change in the penetration proﬁles of ZnO NPs with various chemical pen-
etration enhancing agents [24]. Their studies suggest that the treatment of skin with acetone,
oleic acid, and a mixture of both is able to increase the collection of ZnO NPs in the stratum
corneum and their diffusion through the epidermis. Use of SHG enables the distinction of NPs
from released ions, an advantage that it shares with ﬂuorescence. Despite this important ad-
vancement in the usage of whole tissue microscopy as a primary skin penetration evaluation
technique, the authors did not address their ultimate sensitivity. To ﬁnd published articles that
examine the ultimate sensitivity of their techniques, more overtly quantitative techniques based
around mass spectroscopy must be considered. Research by Gopee et al. has investigated the
penetration of QDs though intact and damaged murine skin in vivo, and used the analysis of Cd
in distal organs (liver and lymph nodes) to evaluate skin penetration of a total dose of 47 pmol
QDs (∼18 pmol/cm2) [8]. Their study provides the limit of detection and the limit of quantiﬁ-
cation for their technique, but suffers due to the necessity of a large portion of QDs to penetrate
the skin in order to achieve appreciable collection in the distal organs over background, with the
ﬁrst detectable difference in barrier defect occurring after 2% of the applied dose collected in
the liver. In a previous study they injected QDs subcutally- mimicking the penetration of 100%
of an applied dose (48 pmol QDs)- and found only 6% of the applied dose in the liver and 1%
in the regional draining lymph nodes [46]. Hence, the liver collection levels required for their
skin penetration study suggests that skin barrier disruption must allow 33% (∼6 pmol/cm2
QDs) of the applied dose to penetrate to a subcutal level for detection. This value is well within
the ability of our system to evaluate. Recent work by Lopez et al. has studied the ability of
sodium lauryl sulfate (SLS) and ultrasound to synergistically impact barrier function against
QDs [21]. A very small but quantiﬁable percentage of the applied QDs with a total dose of
1 μmol QDs (∼564.9 nmol/cm2) were found to penetrate intact epidermis (0.006%-0.078%
of the applied dose, or ∼33.9- 440.7 pmol/cm2 QDs) by mass spectroscopy on mechanically
separated and cleaned dermis. These values are within the sensitivity limits of our system. In
fact, the suggested pathway for their observed QD penetration is via lacunar imperfections of
approximately 48 nm diameter and covering 0.44% of the skin surface area, as discussed in pre-
vious work by Mitragotri’s group [9]. If it is assumed that the majority of QD skin penetration
occurs through these pathways, then it can be estimated that the localized penetration channels
allow 1.36%-17.73% (∼7.7- 100.2 nmol/cm2) of the applied dose to pass, which is well within
the detection limit of our system, and their ultrasound/SLS treatment increases the penetration
of QDs into the dermis to levels of 80%- 99% of the applied dose. The limit of detection and
quantiﬁcation was calculated in a similar manner to that of Gopee et al., but baseline level of Cd
observed in the dermal samples with no QD application was not reported. Whole tissue visible
range confocal microscopy of the separated dermal samples supported their mass spectroscopy
ﬁndings, with rare occurrences of localized spots of relatively high QD concentration, but was
not used to establish a diffusion gradient. When considering mass spectroscopy based studies
a major caveat must be noted, which is that the technique is unable to distinguish between the
penetration of intact NPs or dissolved ions. With an acute application dose of ZnS-capped QDs
this is not a major concern, but may be an important factor with other types of NPs, such as
silver or ZnO NPs [47,48]. The sensitivity evaluation of our system and practical application
for imaging through human epidermis provides a distinct advantage for future studies to de-
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understand the penetration of nanoparticulate substances.
4. Conclusions
The evaluation of NP skin penetration, either to determine risk factors or provide targeted de-
livery is an important area that has far-reaching clinical and toxicological implications. Our
development of a whole tissue confocal imaging system in the near-IR range is a promising
technique that exhibits great potential to address some previous limitations in the ﬁeld, and
help to complement existing state of the art whole tissue imaging techniques. We have op-
timized and characterized our reﬂectance and ﬂuorescence confocal system performance and
found the ability to image QDs in a controlled fashion through ex vivo human epidermis, with
sensitivity surpassing 0.3% of our applied dose, and implemented it to detect QDs penetrat-
ing the skin in an ex vivo barrier disrupted model. Application-optimized system design and
thorough testing enables greater conﬁdence in imaging results and has the potential to expedite
the evaluation of NP formulations and skin barrier alterations. With the movement of imaging
modalities into the near-IR, a well characterized system can provide increased sensitivity and
detection depth for an improved understanding of NP skin permeability.
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